12.70

1.55% -0.20

After Hours: 12.70

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $12.70, with a volume of 323.93K. It is down -1.55% in the last 24 hours and down -8.70% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Previous Close:

$12.90

Open:

$12.94

24h Volume:

323.93K

Relative Volume:

0.66

Market Cap:

$535.69M

Revenue:

$82.71M

Net Income/Loss:

$-102.24M

P/E Ratio:

-2.7137

EPS:

-4.68

Net Cash Flow:

$-76.57M

1W Performance:

-2.08%

1M Performance:

-8.70%

6M Performance:

-15.33%

1Y Performance:

-9.35%

1-Day Range:

$12.60

$13.08

1-Week Range:

$12.60

$13.31

52-Week Range:

$10.60

$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

203

Twitter

@UroGenPharma

Next Earnings Date

2024-08-13

Latest SEC Filings

URGN's Discussions on Twitter

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

Sep 26, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Shares Acquired by Point72 Asset Management L.P. - MarketBeat

Sep 26, 2024

Sep 25, 2024

UroGen Pharma secures $25M loan, eyes FDA drug approval - Investing.com

Sep 25, 2024

Sep 24, 2024

Great Point Partners LLC Increases Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Sep 24, 2024

Sep 23, 2024

UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now - Yahoo Finance

Sep 23, 2024

UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock - Yahoo Finance UK

Sep 23, 2024

Sep 18, 2024

UroGen Pharma reiterates stock target, outperform on strong FDA prospects By Investing.com - Investing.com Australia

Sep 18, 2024

Examining UroGen Pharma Ltd (URGN) more closely is necessary - US Post News

Sep 18, 2024